Tony Hagen is senior managing editor for The Center for Biosimilars®.
Biosimilar Experts Poke Holes in MSK's P-quad Model on Biosimilar Pricing
Biosimilars get short shrift in a proposed pricing model developed by the Drug Pricing Lab at Memorial Sloan Kettering (MSK), experts say.
MSK's Bach Touts Cap on Originator, Biosimilar Profits
Peter Bach, MD, MAPP, and his Drug Pricing Lab at Memorial Sloan Kettering (MSK) argue profit caps will do better than the current biosimilar system.
Harvard Paper: CMS Coding, Other Factors at Fault for Tepid Biosimilar Savings
Biosimilars are intended to save money for the health care system, but for many reasons, they are not succeeding in this mission, Harvard authors argue.
Merck Will Make Its Biosimilars Spinoff a Publicly Traded Company
Following lackluster experience with biosimilar marketing in the United States, Merck moves forward with spinoff plan.
Study: Rapid Adoption Noted for Kanjinti During First Year of Availability
Investigators observed early adoption of the trastuzumab biosimilar Kanjinti in patients with early breast cancer and metastatic breast cancer.
Pfizer Scales Down Biosimilars Activity in China
Pfizer said it has made a business decision to cease production of biosimilars at a $350 million plant it built recently in Hangzhou, China.
Study: Rival Drugs Drive Up Costs
"Shocked" by the threat of competition, originator manufacturers start raising prices long before rival products appear on the scene, investigators found.
Alvotech, Samsung Bioepis Advance on Biosimilars Gameboard
Alvotech closes on $35 million in funding, and Samsung Bioepis gets closer to marketing an adalimumab biosimilar. Alvotech's planned high-tech expansion is pictured.
Biosimilars Education Bill Gains Senate Approval
The Senate has passed a bill requiring the FDA to provide educational information that supports and promotes the adoption of biosimilars.
Biosimilars Litigation: When Safe Harbor Is Not Safe
The Biologics Price Competition and Innovation Act has been around for 10 years, but grey legal areas still abound, Goodwin attorneys note.
Lannett Gears Up for Pivotal Trial of Its Insulin Glargine Candidate
Lannett modifies a pivotal trial design to ensure a smoother ride through the FDA product review.
Alteogen Completes Successful Phase 1 Aflibercept Trial
Alteogen is among a number of contenders vying to bring aflibercept biosimilars to market. Key patents on the originator begin to expire in 2023.
Oncologists' Cost Sensitivity May Drive Biosimilar Uptake
Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of Biosimilars at Cardinal Health, discusses motivating factors that affect use of biosimilars in oncology.
Cardinal Health: Oncologists’ Comfort With Biosimilars Is on the Increase
Survey results show that oncologists are embracing biosimilars not just in supportive care but for therapeutic uses also.
Minnesota Moves to Override Payer Preferences on Biosimilars
Minnesota legislators introduce what could possibly become the first law to curtail payers' rights to determine which biologics patients have access to.
Study: Biosimilar vs Originator Spending on Comparative Efficacy Trials
Investigators evaluated trial spending and reasons for biologics license application failures.
News Briefs: Samsung Bioepis, Cipla, Biocon Report Progress
Biocon and Viatris edge closer to EU marketing authorization for a bevacizumab biosimilar, among other biosimilar business developments.
NCCN Issues Guidelines for Biosimilar Use
The National Comprehensive Cancer Network (NCCN) recommended providers contact their legislators to counteract single-biosimilar payer policies.
Coherus BioSciences Squares Off Against Neulasta Onpro
Sales of the pegfilgrastim oncology support biosimilar Udenyca fell off in late 2020, but Coherus doesn't see orginator company Amgen's advantage lasting much longer.
Fresenius Kabi Maps Out Biosimilar Strategy
The Germany-based company with global operations plans to ramp up its biosimilars portfolio through 2025.
Rituximab Biosimilar Regimen Fails Cost-Effectiveness Test in FL
Although a more costly medicine, obinutuzumab proved more cost-effective over the long run than rituximab biosimilars in follicular lymphoma.
Filling in the Blanks: The Patient-Provider Conversation About Biosimilars
Gary H. Lyman, MD, PhD, provides an expert overview on overcoming the challenges of discussing biosimilars with patients.
Canada Sees Second Adalimumab Biosimilar Launch in a Week
Fresenius Kabi steps into the Canadian market for adalimumab with Idacio.
Coherus Files Adalimumab BLA, Although Intended Concentration Is Unclear
Coherus BioSciences filed a 351(k) biologics license application (BLA) for CHS-1420, an adalimumab biosimilar candidate.
Sandoz Launches Adalimumab Biosimilar in Canada
The launch of Hyrimoz gives Sandoz 5 biosimilars on the Canadian market. National policies on switching have given biosimilars a tailwind.
Celltrion Healthcare Gains EU Authorization for High-Concentration Adalimumab
The marketing of Yuflyma is expected to give Celltrion Healthcare a significant advantage over existing adalimumab biosimilars.
Study: Gender, Internet Habits Influence Biosimilar Acceptance
Patient characteristics are predictive of whether a switch to a biosimilar is likely to be accepted, investigators found.
Amgen Panel Tackles Lessons From Pandemic
Biosimilars, supply chain adjustments, building trust, and international standardization were discussed as means to deliver innovation when it's needed, not after.
Lannett, HEC Pharm Team Up on Insulin Aspart Biosimilar Project
Lannett and HEC Pharm are developing an insulin aspart biosimilar on the heels of their insulin glargine codevelopment project.
DOJ Withdraws Support for ACA Strikedown
Under the Biden administration, the Department of Justice (DOJ) has reversed course and now backs the constitutionality of the Affordable Care Act (ACA).